Last reviewed · How we verify

NP101 — Competitive Intelligence Brief

NP101 (NP101) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: 5-HT1F receptor agonist. Area: Neurology.

phase 3 5-HT1F receptor agonist 5-HT1F receptor Neurology Small molecule Live · refreshed every 30 min

Target snapshot

NP101 (NP101) — NuPathe Inc.. NP101 is a selective serotonin 5-HT1F receptor agonist that reduces migraine pain by constricting cranial blood vessels and inhibiting neuropeptide release.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
NP101 TARGET NP101 NuPathe Inc. phase 3 5-HT1F receptor agonist 5-HT1F receptor
BHV-4157 BHV-4157 Biohaven Therapeutics Ltd. phase 3 5-HT1F receptor agonist 5-HT1F receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (5-HT1F receptor agonist class)

  1. Biohaven Therapeutics Ltd. · 1 drug in this class
  2. NuPathe Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). NP101 — Competitive Intelligence Brief. https://druglandscape.com/ci/np101. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: